P01.066 Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE 2/EORTC 1410 randomized phase II trial

BACKGROUND: Depatux-M is an antibody-drug-conjugate consisting of an antibody (ABT-806) bound to the toxin monomethylauristatin-F. A randomized phase II trial on EGFR-amplified recurrent glioblastomas (GBMs) showed a significant improvement (p=0.06 in the primary analysis, p=0.024 in follow-up analy...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: French, P J, Kros, J, de Heer, I, Ansell, P, Looman, J, Bain, E, Morfouace, M, Gorlia, T, Golfinopoulos, V, van den Bent, M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2018
Gaiak:
Poster Presentations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144572/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.108
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak